A Phase 2a, Proof of Concept Study Evaluating the Safety and Tolerability of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Jan 2025 According to Artax Biopharma media release, company announces achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary oral agent AX-158. And these results confirm the strong Phase 1 and preclinical data package.
22 Jan 2025 Results published in the Artax Biopharma media release.
03 Oct 2024 According to Artax Biopharma media release, company anticipate reporting topline results of this trial in Q4 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com